

## Claims

- [1] A medicament having an inhibitory action against activation of a transcription factor KLF5, which comprises an acyclic polyprenyl compound as an active ingredient.
- [2] A medicament having an inhibitory action against vascular remodeling, which comprises an acyclic polyprenyl compound as an active ingredient.
- [3] A medicament having an inhibitory action against arteriosclerosis, which comprises an acyclic polyprenyl compound as an active ingredient.
- [4] The medicament according to any one of claims 1 to 3, wherein the acyclic polyprenyl compound is a polyprenylcarboxylic acid.
- [5] The medicament according to any one of claims 1 to 3, wherein the acyclic polyprenyl compound is 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentanoic acid.
- [6] The medicament according to any one of claims 1 to 3, wherein the acyclic polyprenyl compound is (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentanoic acid.
- [7] The medicament according to any one of claims 1 to 6, which is in the form of a pharmaceutical composition containing a pharmaceutically acceptable additive for formulations together with an acyclic polyprenyl compound as an active ingredient.
- [8] The medicament according to any one of claims 1 to 7, which is in the form of a pharmaceutical composition for oral administration.